Zanubrutinib plus BR for Waldenström's macroglobulinemia
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of two drugs, zanubrutinib and BR (bendamustine and rituximab), as a first treatment for people with Waldenström's macroglobulinemia. The goal is to see if this combination works better than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Waldenström's macroglobulinemia that hasn't been treated before and is causing symptoms.
- You have a specific genetic marker called MYD88 L265P in your blood or bone marrow.
- Your IgM level is at least 5 g/L (a measure of the abnormal protein in your blood).
- You do not have uncontrolled infections, other cancers, or serious heart problems.
- Your liver and kidney function tests and blood counts are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies zanubrutinib combined with BR (bendamustine and rituximab) in adults newly diagnosed with Waldenström macroglobulinemia (WM) who have symptoms. It may help shrink the abnormal disease and improve symptoms like high blood stickiness, nerve problems, anemia, and other lymphoma-related issues.
This trial tests a new pill (zanubrutinib) combined with a short course of antibody therapy and a lower dose of chemo for people with Waldenström's macroglobulinemia who haven't had strong treatment before. The goal is to see if this gentler combination can control the disease well.
This trial is testing a combination of targeted drugs, including zanubrutinib, for people newly diagnosed with a fast-growing lymphoma called DLBCL. It is designed for patients with certain risk factors that make their lymphoma more aggressive, and it aims to see if these drug combinations can work better than standard treatments.
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
This trial tests a combination of two targeted drugs, zanubrutinib and BGB-11417, for people with Waldenström Macroglobulinemia who have already had at least one prior treatment. The goal is to see if this two-drug approach works better than standard options.
This is an observational study that follows people with Waldenström macroglobulinemia (WM) to learn how well zanubrutinib works and how safe it is. Your results will be tracked in relation to your disease features, including a blood/marrow marker called MYD88.
Hear when a new Waldenström's Macroglobulinemia (WM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.